Table 3.
Comparison between baseline characteristics and clinico-pathological parameters of OC patients analysed by germline BRCA1/2 and multi-gene panel testing
| BRCA1/2 mut | Multi-gene panel mut | All wt | P valuea | P valueb | |
|---|---|---|---|---|---|
| Number of patients | 85 | 4 | 283 | — | — |
| Age at diagnosis (years) | |||||
| Median | 56 | 52.5 | 58 | ||
| Mean | 57.9 | 55.5 | 58 | ||
| Range | 37-81 | 38-79 | 28-84 | 0.9 | 0.8 |
| Age groups (years), n (%) | |||||
| ≤40 | 3 (3.5) | 1 (25) | 22 (7.8) | ||
| 41-50 | 19 (22.4) | 1 (25) | 33 (11.6) | ||
| 51-60 | 31 (36.5) | — | 112 (39.6) | ||
| 61-70 | 22 (25.8) | 1 (25) | 72 (25.4) | ||
| >70 | 10 (11.8) | 1 (25) | 44 (15.6) | 0.45 | 0.77 |
| Cancer site, n (%) | |||||
| Monolateral Ovarian carcinoma | 54 (63.5) | 4 (100) | 236 (83.4) | ||
| Bilateral Ovarian carcinoma | 29 (34.1) | — | 21 (7.4) | ||
| Fallopian tube carcinoma | 0 (0) | — | 2 (0.7) | ||
| Primary peritoneal carcinoma | 2 (2.4) | — | 24 (8.5) | 0.24 | 0.01 |
| FIGO stage, n (%) | |||||
| I | 3 (3.5) | — | 12 (4.2) | ||
| II | 4 (4.7) | 1 (25) | 10 (3.5) | ||
| III | 49 (57.7) | 2 (50) | 39 (13.8) | ||
| IV | 9 (10.6) | — | 11 (3.9) | ||
| Unknown | 20 (23.5) | 1 (25) | 211 (74.6) | 0.43 | 0.03 |
| Histological subtype, n (%) | |||||
| HGSC | 68 (80) | 3 (75) | 194 (68.6) | ||
| Clear cell | 2 (2.4) | — | 6 (2.1) | ||
| Endometrioid | 6 (7.1) | — | 25 (8.8) | ||
| LGSC | 3 (3.5) | — | 2 (0.7) | ||
| Papillary | 3 (3.5) | 1 (25) | 2 (0.7) | ||
| Unknown | 3 (3.5) | — | 54 (19.1) | 0.2 | 0.0004 |
| Personal cancer history before EOC, n (%) | |||||
| Breast cancer history | 15 (17.6) | 2 (50) | 20 (7) | ||
| Other cancers | 1 (12) | 1 (25) | 21 (7.4) | ||
| No cancer history | 69 (81.2) | 1 (25) | 242 (85.6) | 0.001 | 0.001 |
| Surgery, n (%) | |||||
| Staging | 11 (12.9) | 2 (50) | 34 (12) | ||
| Primary cytoreductive | 32 (37.6) | 1 (25) | 126 (44.5) | ||
| Unknown | 42 (49.4) | 1 (25) | 123 (43.5) | 0.1 | 0.07 |
EOC, epithelial ovarian cancer; HGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma; mut, mutated; wt, wild type.
a
Comparison between BRCA1/2 mut versus multi-gene panel mut patients.
b
Comparison between multi-gene panel mut versus all wt patients.